INNPF (InnoCan Pharma) Total Equity: $7.93 Mil (As of Mar. 2026)


INNPF InnoCan Pharma Corp INNPF
56 GF Score
Price $1.70
GF Value $10.03
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Total Equity?

InnoCan Pharma INNPF -10.53% 56 Total Equity is $7.93 Mil as of Mar. 2026. GuruFocus rates INNPF with a GF Score™ of 56/100 and a GF Value™ of $10.03 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma's total equity for the quarter that ended in Mar. 2026 was $7.93 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

InnoCan Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Total Equity Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 9.01 6.23 4.39 7.02 8.24

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.89 6.69 6.63 8.24 7.93
INNPF
56GF Score
InnoCan Pharma Corp INNPF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

InnoCan Pharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=10.522-2.285
=8.24

InnoCan Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=10.845-2.918
=7.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $7.93 Mil mean?
InnoCan Pharma (INNPF) has a Total Equity of $7.93 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for InnoCan Pharma and its competitors.
Is InnoCan Pharma's Total Equity too high?
InnoCan Pharma's current Total Equity is $7.93 Mil. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Total Equity compare to PG and CL?
InnoCan Pharma's Total Equity of $7.93 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Consumer Packaged Goods company?
A good Total Equity depends on the Consumer Packaged Goods industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for InnoCan Pharma and its competitors. InnoCan Pharma's current Total Equity is $7.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current Total Equity is $7.93 Mil. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current Total Equity is $7.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (INNPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for INNPF:

  • Total Equity: $7.93 Mil
  • GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges IP40:GermanyINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score

Get the complete analysis for INNPF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.70
Price
$10.03
GF Value